
CRISPR-Cas9 is a revolutionary gene-editing technology that uses a bacterial defense system adapted for precise DNA modification. The system consists of two components: a guide RNA that directs the system to a specific DNA sequence, and the Cas9 protein that cuts the DNA at that location. Once the DNA is cut, the cell's natural repair mechanisms can be harnessed to insert, delete, or modify genetic material. The technology makes genetic engineering dramatically easier, faster, and cheaper than previous methods, enabling precise edits in virtually any organism.
The technology has transformed genetic research and is enabling new medical treatments, agricultural improvements, and biotechnological applications. CRISPR can correct genetic mutations causing diseases, modify crops for improved traits, engineer cells for therapeutic purposes, and create research models of human diseases. The technology is being used in clinical trials for genetic diseases, cancer therapies, and other conditions. Applications include gene therapy for inherited diseases, cancer treatment using engineered immune cells, agricultural crops with improved traits, and research tools for understanding gene function. Companies like Editas Medicine, CRISPR Therapeutics, and various agricultural biotech firms are developing CRISPR applications.
At TRL 7, CRISPR-Cas9 is widely used in research and is being tested in clinical trials, with some therapies approved for specific conditions. The technology faces challenges including off-target effects where unintended DNA is edited, delivery to target cells in the body, immune responses to the editing system, and ethical concerns about germline editing and enhancement. However, as the technology improves and safety is demonstrated, applications expand. CRISPR could transform medicine by enabling cures for genetic diseases, revolutionize agriculture through precise crop improvement, and enable new biotechnological capabilities, though it also raises profound ethical questions about genetic modification, particularly for human germline editing and enhancement, requiring careful regulation and societal dialogue about appropriate uses.
A biomedical and genomic research center that holds key patents for the use of CRISPR-Cas9 in eukaryotic cells.
Germany · Research Lab
A research institute founded to allow Emmanuelle Charpentier to continue her research into CRISPR-Cas9 and bacterial pathogens.
Switzerland · Company
A leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.
United States · Company
A clinical-stage genome editing company dedicated to developing a class of genomic medicines using CRISPR technology.
United States · Company
A biotechnology company developing curative therapeutics using CRISPR/Cas9 gene editing.
United States · Company
A company pioneering the use of base editing, a new class of genetic medicines that offer precision gene editing.
United States · Company
A clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies.
United States · Startup
A biotech company harnessing the diversity of nature to build the next generation of CRISPR products, specifically for diagnostics and ultra-compact editing.
United States · Company
A genome engineering company that provides synthetic RNA kits and engineered cells to accelerate CRISPR research.
A company using CRISPR to engineer pig organs for human transplant (xenotransplantation).
An agriculture technology company using CRISPR to develop new varieties of fruits and vegetables.
United Kingdom · Startup
An agricultural biotechnology company using CRISPR to improve tropical crops like bananas, coffee, and rice.